Predictors for short bowel syndrome in Crohn's disease

Dig Liver Dis. 2020 Dec;52(12):1455-1460. doi: 10.1016/j.dld.2020.08.029. Epub 2020 Sep 14.

Abstract

Background and aim: Patients with Crohn's disease (CD) are at risk for short bowel syndrome (SBS). We investigated independent predictors for SBS in these patients to allow the development of preventive strategies.

Methods: All adult patients seen at the Nancy University hospital for CD or SBS between 2012 and 2019 were eligible for inclusion in this case-control study. Each CD patient with SBS was matched to 9 controls.

Results: 410 CD patients were included (369 without SBS and 41 with SBS). Subjects with SBS underwent significantly more bowel resections (median value of 3 vs 1, p<0.0001) and median time before the first surgery was not different than controls (6 vs 4 years, p=0.59). A higher need for parenteral support was found in end-jejunostomy SBS than in jejunocolic and jejunoileal SBS (70.6% vs 25% and 0%, p=0.0031). Montreal B1 behavior (OR 0.02, CI 95% 0-0.08) and budesonide treated-patients (OR=0.03, CI 95% 0.003-0.2) were at lower risk of SBS, while IV steroid treated-patients were at higher risk (OR=8.5, CI 95% 3.0-24.9).

Conclusion: Montreal B1 behavior, IV steroids and budesonide use are influencing predictors for this complication. These predictors should be assessed in daily clinical practice to prevent SBS occurrence.

Keywords: Crohn's disease; Inflammatory bowel diseases; Risk factors; Short bowel syndrome; Surgery.

MeSH terms

  • Adult
  • Budesonide / therapeutic use
  • Case-Control Studies
  • Crohn Disease / epidemiology*
  • Crohn Disease / prevention & control
  • Crohn Disease / therapy
  • Female
  • Humans
  • Intestine, Small / pathology
  • Jejunostomy
  • Male
  • Parenteral Nutrition / adverse effects
  • Prognosis
  • Regression Analysis
  • Short Bowel Syndrome / epidemiology*
  • Short Bowel Syndrome / therapy
  • Steroids / administration & dosage
  • Young Adult

Substances

  • Steroids
  • Budesonide